natgillin/translations-raw huggingface dataset:
De patienter, der blev behandlet med sitagliptin, udviste et signifikant gennemsnitligt fald i kropsvægt i forhold til baseline sammenlignet med en signifikant vægtøgning hos patientgruppen, der fik glipizid (-1,5 versus +1,1 kg).
Patients treated with sitagliptin exhibited a significant mean decrease from baseline in body weight (-1.5 kg) compared to a significant weight gain in patients administered glipizide (+1.1 kg).
Ristfor er også indiceret som tillægsbehandling til insulin (dvs. tripel kombinationsbehandling) som supplement til diæt og motion til forbedring af den glykæmiske kontrol hos patienter, når stabil dosering af insulin og metformin alene ikke giver tilstrækkelig glykæmisk kontrol.
Ristfor is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Når Ristfor anvendes sammen med et sulfonylurinstof, kan en lavere dosis af sulfonylurinstoffet være nødvendig for at reducere risikoen for hypoglykæmi (se pkt.
When Ristfor is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).
Ristfor er en kombination af to antihyperglykæmiske lægemidler med komplementære virkningsmekanismer til forbedring af glykæmisk kontrol hos patienter med type 2-diabetes: sitagliptinphosphat, en dipeptidylpeptidase-4-hæmmer (DPP-4), og metforminhydrochlorid, der tilhører biguanidklassen.
Ristfor combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Når Ristfor anvendes sammen med insulin, kan det være nødvendigt at nedsætte insulindosis for at reducere risikoen for hypoglykæmi (se pkt.
When Ristfor is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4).
Brug ikke Ristfor efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned.
The expiry date refers to the last day of the month.
Ved akut forværring af nyrefunktionen akkumuleres metformin, hvilket øger risikoen for laktacidose.
Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.
Der blev ikke observeret behandlingsrelaterede bivirkninger i fertiliteten hos han- og hunrotter, der blev behandlet med sitagliptin før og under parringsperioden.
No treatment related effects on fertility were observed in male and female rats given sitagliptin prior to and throughout mating.
Er De i tvivl, så spørg lægen, apotekspersonalet eller sundhedspersonalet, før De tager Ristfor.
If you are not sure, talk to your doctor, pharmacist or nurse before taking Ristfor.
Ristfor er indiceret som supplement til diæt og motion til forbedring af den glykæmiske kontrol hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin alene eller hos de patienter, som allerede er i behandling med kombinationen af sitagliptin og metformin.
Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Nogle patienter har oplevet følgende bivirkninger, når de har taget dette lægemiddel sammen med pioglitazon:
Some patients have experienced the following side effects while taking this medicine in combination with pioglitazone:
• Ranolazin, et lægemiddel til behandling af brystsmerter (angina pectoris).
• ranolazine, a medicine used to treat angina
- Øvrige indholdsstoffer: I tabletkernen: Mikrokrystallinsk cellulose (E460), povidon K 29/32 (E1201), natriumlaurilsulfat, og natriumstearylfumarat.
- The other ingredients are: In the tablet core: microcrystalline cellulose (E460), povidone K 29/32 (E1201), sodium lauril sulfate, and sodium stearyl fumarate.
Ristfor er indiceret som tripel kombinationsbehandling sammen med en peroxisom proliferatoraktiveret receptor-gamma (PPAR)-agonist (dvs. et glitazon) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin og en PPAR-agonist.
Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
B. BETINGELSER ELLER BEGRÆNSNINGER VEERØRENDE UDLEVERING OG ANVENDELSE
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Dosis bør doseres som sitagliptin 50 mg to gange dagligt (100 mg i alt pr. dag), og metformin bør gives i en dosis svarende til den, som allerede tages.
The dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.
Når nyrefunktionen er nedsat, er renal clearance nedsat i forhold til kreatinins, og derfor er halveringstiden for elimination forlænget, hvilket fører til øget plasmakoncentration af metformin.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 h. When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER
MINIMUM PARTICULARS TO APPEAR ON BLISTERS
Nogle patienter har oplevet følgende bivirkninger, når de har taget dette lægemiddel sammen med et sulfonylurinstof, fx glimepirid:
Some patients have experienced the following side effects while taking this medicine with a sulphonylurea such as glimepiride:
Kontakt straks Deres læge, hvis De har taget mere end den foreskrevne dosis af dette lægemiddel.
If you take more than the prescribed dosage of this medicine, contact your doctor immediately.
Kapselformet, rød filmovertrukken tablet med "577" præget på den ene side.
Capsule-shaped, red film-coated tablet with “577” debossed on one side.
Øvre abdominalsmerter
Uncommon upper abdominal pain
I denne undersøgelse var incidensen af hypoglykæmi den samme, som blev rapporteret for patienter, der var blevet behandlet med sitagliptin eller placebo.
In this study there was a similar incidence of hypoglycaemia reported for patients treated with sitagliptin or placebo.
84 filmovertrukne tabletter.
84 film-coated tablets.
Ændring i kropsvægt i forhold til baseline var den samme for patienter, der blev behandlet med sitagliptin i forhold til placebo.
Change from baseline in body weight was similar for patients treated with sitagliptin relative to placebo.
Kapselformet, lyserød filmovertrukken tablet med "515" præget på den ene side.
Capsule-shaped, pink film-coated tablet with “515” debossed on one side.
Undersøgelser af sitagliptin i kombination med metformin I en 24-ugers placebokontrolleret klinisk undersøgelse til vurdering af effekt og sikkerhed ved sitagliptin 100 mg en gang dagligt som supplement til metformin gav sitagliptin signifikant forbedring af glykæmiske parametre sammenlignet med placebo.
Studies of sitagliptin in combination with metformin In a 24-week, placebo-controlled clinical study to evaluate the efficacy and safety of the addition of sitagliptin 100 mg once daily to ongoing metformin, sitagliptin provided significant improvements in glycaemic parameters compared with placebo.
98 filmovertrukne tabletter.
98 film-coated tablets.
196 filmovertrukne tabletter
196 film-coated tablets
Nedsat leverfunktion Ristfor må ikke anvendes til patienter med nedsat leverfunktion (se pkt.
Hepatic impairment Ristfor must not be used in patients with hepatic impairment (see section 5.2).
Til de forskellige metformindoser findes Ristfor i styrker på 50 mg sitagliptin og 850 mg metforminhydrochlorid eller 1.000 mg metforminhydrochlorid.
For the different doses on metformin, Ristfor is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1,000 mg metformin hydrochloride.
Der er ikke udført behandlingsmæssige kliniske undersøgelser med Ristfor-tabletter, men Ristfors bioækvivalens er blevet påvist, når det gives sammen med sitagliptin og metformin (se pkt.
There have been no therapeutic clinical trials conducted with Ristfor tablets however bioequivalence of Ristfor with co-administered sitagliptin and metformin has been demonstrated (see section 5.2).
112 filmovertrukne tabletter
112 film-coated tablets
Behandlingen med Ristfor skal afbrydes forud for eller på tidspunktet for billeddiagnostiske procedurer og først genoptages mindst 48 timer herefter, forudsat at nyrefunktionen er blevet vurderet og fundet stabil (se pkt.
Ristfor should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.3 and
• Lægemidler mod smerter og betændelseslignende tilstande (NSAID'er og COX-2-hæmmere,
• medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib)
Sitagliptin som supplement til glimepirid og metformin gav signifikante forbedringer af glykæmiske parametre.
The addition of sitagliptin to glimepiride and metformin provided significant improvements in glycaemic parameters.
Kombinationsbehandlinger, der kræver forholdsregler før anvendelse Visse lægemidler kan påvirke nyrefunktionen negativt, hvilket kan øge risikoen for laktacidose, f.eks. NSAID'er, herunder selektive cyklooxygenase (COX) II-hæmmere, ACE-hæmmere, angiotensin IIreceptorantagonister og diuretika, især loop-diuretika.
Some medicinal products can adversely affect renal function, which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics.
Kontakt lægen, apoteket eller sundhedspersonalet, før De tager Ristfor: - Hvis De har eller har haft en sygdom i bugspytkirtlen (f.eks. pankreatitis).
Talk to your doctor or pharmacist before taking Ristfor: - if you have or have had a disease of the pancreas (such as pancreatitis) - if you have or have had gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.
Reduktionen i kropsvægt ved en kombination af sitagliptin og metformin var den samme som den, der blev observeret med metformin alene eller placebo.
The decrease in body weight with the combination of sitagliptin and metformin was similar to that observed with metformin alone or placebo; there was no change from baseline for patients on sitagliptin alone.
Tel: +39 06 361911 doccen@merck.com
Tel: +39 06 361911 medicalinformation.it@merck.com
Behandling med Ristfor skal afbrydes på tidspunktet for kirurgi under generel, spinal eller epidural anæstesi og må tidligst genoptages 48 timer efter kirurgi eller genoptagelse af oral ernæring og under forudsætning af, at nyrefunktionen er blevet vurderet og fundet stabil.
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.
Der er ingen klinisk erfaring fra patienter med svær leverinsufficiens (ChildPugh score >9), men da sitagliptin primært elimineres renalt, forventes svær leverinsufficiens ikke at påvirke sitagliptins farmakokinetik.
However, because sitagliptin is primarily renally eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin.
Nyrefunktionen
Renal function
Desuden indeholder filmovertrækket: Poly(vinylalkohol), macrogol 3350, talcum (E553b), titandioxid (E171), rød jernoxid ((E172) og sort jernoxid (E172).
In addition, the film coating contains: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), and iron oxide black (E172).
Undersøgelse af sitagliptin i kombination med metformin og insulin En 24-ugers placebokontrolleret undersøgelse blev designet til at evaluere effekt og sikkerhed af sitagliptin (100 mg en gang dagligt) som supplement til insulin (ved stabil dosis i mindst 10 uger) med eller uden metformin (mindst 1500 mg).
Study of sitagliptin in combination with metformin and insulin A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to insulin (at a stable dose for at least 10 weeks) with or without metformin (at least 1,500 mg).
Mave-tarm-kanalen Diarré
Gastrointestinal disorders diarrhoea
Incidensen af hypoglykæmi hos patienter, der blev behandlet med sitagliptin, var den samme som for placebo.
The observed incidence of hypoglycaemia in patients treated with sitagliptin was similar to placebo.
Det gennemsnitlige fordelingsvolumen ved steady state efter en enkelt intravenøs dosis på 100 mg sitagliptin til raske forsøgspersoner er ca. 198 l. Den fraktion af sitagliptin, som er reversibelt bundet til plasmaproteiner, er lav (38%).
The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 litres.
Patienterne fik sitagliptin (7.332) 100 mg dagligt (eller 50 mg dagligt, hvis eGFR ved baseline var ≥ 30 og < 50 ml/min/1,73 m2) eller placebo (7.339) som supplement til standardbehandling målrettet de regionale standarder for HbA1c og kardiovaskulære risikofaktorer.
The TECOS was a randomised study in 14,671 patients in the intention-to-treat population with an HbA1c of ≥ 6.5 to 8.0 % with established CV disease who received sitagliptin (7,332) 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m2) or placebo (7,339) added to usual care targeting regional standards for HbA1c and CV risk factors.
Undersøgelse af sitagliptin i kombination med metformin og en PPAR-agonist Et 26-ugers placebokontrolleret studie blev designet til at evaluere sitagliptins effekt og sikkerhed (100 mg en gang dagligt) som supplement til kombinationen pioglitazon plus metformin.
Study of sitagliptin in combination with metformin and a PPAR agonist A 26-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to the combination of pioglitazone and metformin.
Patienterne skal informeres om at stoppe med at tage metformin og øjeblikkeligt søge lægehjælp ved symptomer, der kan give mistanke om laktacidose.
In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention.
Sitagliptin 100 mg en gang dagligt som supplement til igangværende insulin- + metforminbehandling (N=223)
Sitagliptin 100 mg once daily added to ongoing insulin + metformin therapy (N=223)
Undersøgelse af sitagliptin i kombination med metformin og et sulfonylurinstof En 24-ugers placebokontrolleret undersøgelse blev designet til at vurdere effekt og sikkerhed af sitagliptin (100 mg en gang dagligt) som supplement til glimepirid (alene eller i kombination med metformin).
Study of sitagliptin in combination with metformin and a sulphonylurea A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to glimepiride (alone or in combination with metformin).
Nogle af disse tyder på neural toksicitet: Vejrtrækning med åben mund, spytafsondring, hvid skummende opkastning, ataksi, skælven, nedsat aktivitet og/eller krum stilling.
Transient treatment-related physical signs, some of which suggest neural toxicity, such as open-mouth breathing, salivation, white foamy emesis, ataxia, trembling, decreased activity, and/or hunched posture were observed in dogs at exposure levels approximately 23 times the clinical exposure level.
Til patienter, der ikke er tilstrækkeligt kontrolleret på metformin alene, bør den normale startdosis doseres som 50 mg sitagliptin to gange dagligt (100 mg i alt pr. dag) plus den dosis metformin, som allerede tages.
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken.
hæmmere).
(pancreatitis).
Den maksimale daglige dosis er 25 mg.
Maximum daily dose is 25 mg.
Peak-plasmakoncentrationer (median Tmax) forekom 1-4 timer efter dosering, gennemsnitlig plasmaAUC for sitagliptin var 8,52 µM•hr, Cmax var 950 nM. Sitagliptins absolutte biotilgængelighed er ca. 87%.
Following oral administration of a 100-mg dose to healthy subjects, sitagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post-dose, mean plasma AUC of sitagliptin was 8.52 M•hr, Cmax was 950 nM.
Ristfor 50 mg/850 mg filmovertrukne tabletter.
Ristfor 50 mg/850 mg film-coated tablets
Den maksimale daglige dosis er 100 mg.
Maximum daily dose is 100 mg.
Analyse af resultaterne for overvægtige patienter, der blev behandlet med metformin efter svigt af diæt alene, viste: - signifikant reduktion af den absolutte risiko for diabetesrelaterede komplikationer i metformingruppen (29,8 hændelser/1.000 patientår) versus diæt alene (43,3 hændelser/1.000 patientår), p=0,0023, og versus den kombinerede sulfonylurinstof/insulinmonoterapigruppe (40,1 hændelser/1.000 patientår), p=0,0034.
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: - a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034 - a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021) - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01).
Absolut biotilgængelighed for en 500 mg metformintablet er ca. 50-60% hos raske forsøgspersoner.
After an oral dose of metformin, Tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60 % in healthy subjects.
Sitagliptin 100 mg en gang dagligt som supplement til igangværende behandling med pioglitazon + metformin (N=152)
Sitagliptin 100 mg once daily added to ongoing pioglitazone + metformin therapy (N=152)
Den maksimale daglige dosis er 50 mg.
Maximum daily dose is 50 mg.
Ristfor er indiceret som supplement til diæt og motion i kombination med et sulfonylurinstof (dvs. tripel kombinationsbehandling) hos patienter, der ikke er tilstrækkeligt kontrolleret på den maksimalt tolererede dosis metformin og sulfonylurinstof.
Ristfor is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
- Hvis De har en alvorlig infektion eller har væskemangel.
- if you have a severe infection or are dehydrated - if you are going to have an X-ray where you will be injected with a dye.
Ristfor 50 mg/1.000 mg filmovertrukne tabletter.
Ristfor 50 mg/1,000 mg film-coated tablets
Den maksimale daglige dosis er 3.000 mg.
Maximum daily dose is 3000 mg.
Sitagliptin 100 mg en gang dagligt som supplement til metforminbehandling (N=453)
Sitagliptin 100 mg once daily added to ongoing metformin therapy (N=453)
EU/1/10/620/009 14 filmovertrukne tabletter EU/1/10/620/010 28 filmovertrukne tabletter EU/1/10/620/011 56 filmovertrukne tabletter EU/1/10/620/021 60 filmovertrukne tabletter EU/1/10/620/012 112 filmovertrukne tabletter EU/1/10/620/013 168 filmovertrukne tabletter EU/1/10/620/022 180 filmovertrukne tabletter EU/1/10/620/014 196 filmovertrukne tabletter EU/1/10/620/015 50 x 1 filmovertrukne tabletter EU/1/10/620/016 196 (2 x 98) filmovertrukne tabletter EU/1/10/620/018 168 (2 x 84) filmovertrukne tabletter
EU/1/10/620/009 14 film-coated tablets EU/1/10/620/010 28 film-coated tablets EU/1/10/620/011 56 film-coated tablets EU/1/10/620/021 60 film-coated tablets EU/1/10/620/012 112 film-coated tablets EU/1/10/620/013 168 film-coated tablets EU/1/10/620/022 180 film-coated tablets EU/1/10/620/014 196 film-coated tablets EU/1/10/620/015 50 x 1 film-coated tablets EU/1/10/620/016 196 (2 x 98) film-coated tablets EU/1/10/620/018 168 (2 x 84) film-coated tablets
Den maksimale daglige dosis er 2.000 mg.
Maximum daily dose is 2000 mg.
- Lægen har ordineret Ristfor til Dem personligt.
- This medicine has been prescribed for you only.
: Sitagliptin 50 mg + metformin 500 mg (N=183) Initialbehandling (to gange dagligt)
Sitagliptin 50 mg + metformin 500 mg (N=183)
EU/1/10/620/001 14 filmovertrukne tabletter EU/1/10/620/002 28 filmovertrukne tabletter EU/1/10/620/003 56 filmovertrukne tabletter EU/1/10/620/019 60 filmovertrukne tabletter EU/1/10/620/004 112 filmovertrukne tabletter EU/1/10/620/005 168 filmovertrukne tabletter EU/1/10/620/020 180 filmovertrukne tabletter EU/1/10/620/006 196 filmovertrukne tabletter EU/1/10/620/007 50 x 1 filmovertrukne tabletter EU/1/10/620/008 196 (2 x 98) filmovertrukne tabletter EU/1/10/620/017 168 (2 x 84) filmovertrukne tabletter
EU/1/10/620/001 14 film-coated tablets EU/1/10/620/002 28 film-coated tablets EU/1/10/620/003 56 film-coated tablets EU/1/10/620/019 60 film-coated tablets EU/1/10/620/004 112 film-coated tablets EU/1/10/620/005 168 film-coated tablets EU/1/10/620/020 180 film-coated tablets EU/1/10/620/006 196 film-coated tablets EU/1/10/620/007 50 x 1 film-coated tablets EU/1/10/620/008 196 (2 x 98) film-coated tablets EU/1/10/620/017 168 (2 x 84) film-coated tablets
Den maksimale daglige dosis er 1.000 mg.
Maximum daily dose is 1000 mg.
- Hvis De for nylig har haft et hjerteanfald eller har alvorlige kredsløbsproblemer, herunder shock eller vejrtrækningsbesvær.
depending on how your kidneys are working - if you have recently had a heart attack or have severe circulatory problems, such as ‘shock' or breathing difficulties - if you have liver problems - if you drink alcohol to excess (either every day or only from time to time) - if you are breast-feeding.
I kliniske undersøgelser ændrede sitagliptin ikke farmakokinetikken for metformin, glyburid, simvastatin, rosiglitazon, warfarin eller orale kontraceptiva betydeligt.
In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic cationic transporter (OCT).
HbA1c (%) i 24. uge HbA1c (%) i 26. uge Gennemsnit beregnet ved mindste kvadraters metode justeret for anvendelse af insulin ved besøg 1 (forblandet versus ikkeforblandet [middellangtidsvirkende eller langtidsvirkende]) og baseline-værdi.
Least squares mean adjusted for insulin use at Visit 1 (pre-mixed vs. non-pre-mixed [intermediate- or long-acting]), and baseline value.
- Hvis De tager anden diabetesmedicin, sulfonylurinstof eller insulin, sammen med Ristfor, da De så kan opleve lavt blodsukker (hypoglykæmi).
This is sometimes called insulin-dependent diabetes - if you have or have had an allergic reaction to sitagliptin, metformin, or Ristfor (see section 4) - if you are taking a sulphonylurea or insulin, diabetes medicines, together with Ristfor, as you may experience low blood sugar levels (hypoglycaemia).